Zymeworks BC Inc (NASDAQ:ZYME) price on Friday, December 27, remained unchanged to $14.50.
A look at the stock’s price movement, the close in the last trading session was $14.50, moving within a range at $13.96 and $14.5866. The beta value (5-Year monthly) was 1.157. Turning to its 52-week performance, $17.70 and $7.97 were the 52-week high and 52-week low respectively. Overall, ZYME moved 1.40% over the past month.
Zymeworks BC Inc’s market cap currently stands at around $1.01 billion, with investors looking forward to this quarter’s earnings report slated for in January.
Analysts have a consensus estimate of 49.23M for the company’s revenue for the quarter, with a low and high estimate of 12.32M and 120M respectively. The average forecast suggests up to a 190.84% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 89.47M, representing a 17.71% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ZYME is a 50% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
4 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 3 recommend ZYME as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ZYME’s current price about 5.60% and 1.86% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 55.54, while 7-day volatility ratio is 5.47% and 5.21% in the 30-day chart. Further, Zymeworks BC Inc (ZYME) has a beta value of 1.11, and an average true range (ATR) of 0.75. Analysts have given the company’s stock an average 52-week price target of $19, forecast between a low of $12 and high of $28. Looking at the price targets, the low is 17.24% off current price level while to achieve the yearly target high, price needs to move -93.1%. Nonetheless, investors will most likely welcome a -31.03% jump to $19 which is the analysts’ median price.
If we refocus on Zymeworks BC Inc (NASDAQ:ZYME), historical trading data shows that trading volumes averaged 0.6 over the past 10 days and 503.92K over the past 3 months. The company’s latest data on shares outstanding shows there are 69.58 million shares.
The 4.03% of Zymeworks BC Inc’s shares are in the hands of company insiders while institutional holders own 98.92% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 4.63 million on 2024-11-29, giving us a short ratio of 8.31. The data shows that as of 2024-11-29 short interest in Zymeworks BC Inc (ZYME) stood at 829.0000000000001 of shares outstanding, with shares short falling to 4.7 million registered in 2024-10-31. Current price change has pushed the stock 39.56% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ZYME stock continues to rise going into the next quarter.
